Trial Profile
A Phase 1 Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Isotretinoin
- Indications Adenoid cystic carcinoma; Advanced breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Kidney-neoplasms; Lung cancer; Mesothelioma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 02 Apr 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.